Virtual Incision Announces $46 Million Financing to Advance First-of-its-Kind MIRA Surgical Platform

Virtual Incision宣布4600万美元融资,推进首个同类MIRA手术平台

2021-12-01 18:30:07 BioSpace

本文共2193个字,阅读需6分钟

IDE clinical study of robotic-assisted MIRA Surgical Platform currently underway for laparoscopic colon surgery LINCOLN, Neb., & PLEASANTON, Calif.--(BUSINESS WIRE)-- Virtual Incision Corporation, a medical device company pioneering first-of-its-kind miniaturized robots for laparoscopic surgery, today announced it has raised $46 million in a Series C funding round. The round was led by Endeavour Vision and Baird Capital, with participation from returning investor Bluestem Capital and others. The funds will be used to support regulatory and clinical programs leading to the commercialization of the company’s MIRA® (“miniaturized in vivo robotic assistant”) Surgical Platform. “We are thrilled to have Endeavour Vision and Baird lead this round of financing at this important stage of our company’s growth, along with the continued strong support of our largest shareholder, Bluestem,” said John Murphy, Virtual Incision’s president and CEO. “Virtual Incision’s goal is to transform surgery by providing a practical and hassle-free platform that will enable efficient, effective, and affordable access to robotic-assisted technology, regardless of the site of care. We are excited that this funding will support our efforts to advance MIRA, so that more patients can ultimately experience the benefits of minimally invasive surgery.” The company recently announced the world’s first surgery using the MIRA Surgical Platform performed by Michael A. Jobst, M.D., at Bryan Medical Center in Lincoln, Neb. The robotically assisted right hemicolectomy procedure was performed as part of a clinical study of MIRA under an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA). The study, which the company believes is progressing well, is currently being conducted at a limited number of U.S. hospitals in support of the system’s regulatory pathway to approval. “The ability of MIRA to successfully perform colon resection—a challenging procedure in minimally invasive surgery that requires multi-quadrant anatomical access and significant robotic strength—demonstrates the huge potential of the platform,” said Shane Farritor, Ph.D., Virtual Incision’s co-founder and chief technology officer. “This funding milestone represents a step forward in our goal to deliver a miniaturized solution for robot-assisted laparoscopic surgery, regardless of the site of care.” “While the demand for robotically assisted surgery continues to grow because of its clear benefits for patients, there are still challenges that hinder broader adoption, such as high cost, complex set-up, and required space and infrastructure,” said Robert Barmann, Partner, Endeavour Vision. “MIRA is intended to address the limitations associated with current main-frame robotic-assisted surgery systems through its small, mobile design that is streamlined for routine high volume procedures. We look forward to partnering with Virtual Incision to advance this innovative technology.” “MIRA is a space-saving solution designed to help hospitals and ambulatory surgery centers leverage their existing infrastructure to perform surgery efficiently while offering a low total cost of ownership,” said Amy Len Kobe, Principal with Baird Capital. “Consistent with our venture team’s investment goals, the MIRA platform has the ability to improve care for patients, physicians, providers, and payors. And, best of all, it’s unlike any other surgical robotic platform available today.” Funding from the round will also be used to support the company’s research and development pipeline. Beyond its initial device design for colon resection, Virtual Incision has begun developing a family of mini-robots optimized for additional operations such as hernia repair, gallbladder removal, hysterectomy, sleeve gastrectomy and others, potentially enabling millions more surgical procedures each year. With its foundational intellectual property—including more than 200 patents and applications—Virtual Incision is poised to lead the next wave of innovation in robotic-assisted surgery with the pioneering MIRA system. About the MIRA® Surgical Platform Virtual Incision’s MIRA (“miniaturized in vivo robotic assistant”) Surgical Platform features a small, self-contained surgical device that is inserted through a single midline umbilical incision in the patient’s abdomen. Virtual Incision’s technology is designed to support multi-quadrant abdominal surgeries utilizing existing minimally invasive tools and techniques familiar to laparoscopic surgeons, and does not require a dedicated operating room or specialized infrastructure. Because of its much smaller size, the device is expected to be significantly less expensive than existing robotically-assisted surgical devices. About Virtual Incision Virtual Incision is reimagining robotically-assisted surgery, with simple innovations offering mobility, flexibility, and accessibility to provide minimally invasive options to more patients. The company is developing the MIRA Surgical Platform, a first-of-its-kind miniaturized surgical device, focusing first on colon resection, with follow-on specialty robots for additional potential applications. The company is headquartered in Lincoln, Neb. For more information, visit https://virtualincision.com/. Cautionary Note Regarding Forward-Looking Statements This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on a number of assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005342/en/ Lara Lingenbrink Health+Commerce Lara@healthandcommerce.com 858-525-1414 Source: Virtual Incision View this news release online at: http://www.businesswire.com/news/home/20211130005342/en
机器人辅助MIRA手术平台用于腹腔镜结肠手术的IDE临床研究 内布拉斯加州林肯市和加利福尼亚州普莱森顿市--(商业网)--虚拟切口公司,一家医疗设备公司,开创了第一个用于腹腔镜手术的微型机器人,今天宣布它已经在C轮融资中筹集了4600万美元。该轮由Endeavour Vision和Baird Capital牵头,回归投资者Bluestem Capital和其他公司参与。这笔资金将用于支持监管和临床项目,导致该公司的米拉®(“小型化体内机器人助手”)手术平台商业化。 Virtual Insision总裁兼首席执行官约翰·墨菲(John Murphy)表示:“在我们公司发展的这一重要阶段,我们很高兴奋进愿景(Endeavour Vision)和贝尔德(Baird)领导了这一轮融资,并得到了我们最大股东Bluestem的持续大力支持。”“虚拟切口的目标是通过提供一个实用和无麻烦的平台来改变外科手术,该平台将使人们能够高效、有效和负担得起的获得机器人辅助技术,无论护理地点如何。我们感到兴奋的是,这笔资金将支持我们推进MIRA的努力,以便更多的患者最终能够体验到微创手术的好处。“ 该公司最近宣布了世界上第一个使用MIRA手术平台的手术,由迈克尔·A·乔布斯特医学博士在内布拉斯加州林肯市的布莱恩医学中心进行。机器人辅助右半结肠切除术是根据美国食品药品监督管理局(FDA)的研究设备豁免(IDE)进行的MIRA临床研究的一部分。该公司认为这项研究进展顺利,目前正在有限数量的美国医院进行,以支持该系统的监管批准途径。 虚拟切口的联合创始人兼首席技术官谢恩·法里托(Shane Farritor)博士说:“MIRA成功进行结肠切除的能力展示了该平台的巨大潜力。”结肠切除是微创手术中一项具有挑战性的手术,需要多象限解剖访问和强大的机器人力量。“这一融资里程碑标志着我们在为机器人辅助腹腔镜手术提供小型化解决方案的目标上向前迈出了一步,无论护理地点如何。” Endeavour Vision合伙人罗伯特·巴曼(Robert Barmann)表示:“虽然机器人辅助手术的需求继续增长,因为它对患者有明显的好处,但仍存在阻碍更广泛采用的挑战,如高成本、复杂的设置以及所需的空间和基础设施。”“Mira旨在通过其小型、可移动的设计来解决与当前主框架机器人辅助手术系统相关的局限性,该设计简化了常规高容量手术。我们期待着与虚拟切口合作,推进这项创新技术。“ 贝尔德资本(Baird Capital)的负责人艾米·莱恩·科比(Amy Len Kobe)表示:“Mira是一种节省空间的解决方案,旨在帮助医院和门诊手术中心利用现有的基础设施高效进行手术,同时提供低总拥有成本。”“与我们风险团队的投资目标一致,MIRA平台有能力改善对病人、医生、提供者和支付者的护理。最重要的是,它不像今天可用的任何其他手术机器人平台。“ 这一轮的资金也将用于支持该公司的研究和开发管道。除了最初的结肠切除设备设计之外,虚拟切口已经开始开发一系列迷你机器人,为疝修补、胆囊切除、子宫切除、袖状胃切除等额外手术进行优化,每年可能会增加数百万次手术。凭借其基础知识产权--包括200多项专利和申请--虚拟切口准备用开创性的MIRA系统引领机器人辅助手术的下一波创新。 关于米拉·®手术平台 虚拟切口的MIRA(“小型化在体机器人助手”)手术平台具有一个小的、独立的手术设备,通过患者腹部的一个中线脐带切口插入。虚拟切口的技术旨在支持多象限腹部手术,利用现有的腹腔镜外科医生熟悉的微创工具和技术,不需要专用的手术室或专门的基础设施。由于其体积小得多,该设备预计将比现有的机器人辅助手术设备便宜得多。 关于虚拟切口 虚拟切口正在重新想象机器人辅助手术,通过简单的创新提供机动性、灵活性和可及性,为更多患者提供微创选择。该公司正在开发MIRA外科手术平台,这是一种首创的小型化外科手术设备,首先专注于结肠切除,后续专业机器人用于其他潜在应用。公司总部设在内布拉斯加州林肯市。有关更多信息,请访问https://virtualincision.com/。 关于前瞻性陈述的警告性说明 本通讯包含构成1995年《私人证券诉讼改革法》意义内的“前瞻性陈述”的陈述。前瞻性陈述包括但不限于关于我们的计划、信念、预期和假设的陈述,以及其他不一定是历史事实的陈述。请注意,这些前瞻性陈述只是预测,涉及风险和不确定性。此外,任何前瞻性陈述仅限于其发表之日,我们不打算更新或修改任何前瞻性陈述。本通讯亦包含与本公司业务及行业有关的市场数据,其中包括基于本公司认为合理及对本通讯日期之预测最重要之若干假设而作出之预测。如果我们的任何假设被证明是不正确的,我们的实际结果可能与我们基于这些假设的预测有很大差异。 在businesswire.com查看源版本:https://www.businesswire.com/news/home/20211130005342/en/ 劳拉·林根布林克 健康+商业 @healthandcommerce.com 858-525-1414 来源:虚拟切口 在网上查看此新闻稿: http://www.businesswire.com/news/home/20211130005342/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文